Combining 2-deoxy-D-glucose with electron transport chain blockers: a double-edged sword.
Boutros
Jean
J
Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
Almasan
Alexandru
A
D000818:Animals; D000968:Antimycin A / Q000494:pharmacology; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002470:Cell Survival / Q000187:drug effects; D003110:Colonic Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000473:pathology; D003847:Deoxyglucose / Q000008:administration & dosage / Q000494:pharmacology*; D004357:Drug Synergism; D004579:Electron Transport / Q000187:drug effects; D005978:Glutathione / Q000378:metabolism; D019803:Glutathione Disulfide / Q000378:metabolism; D045325:HCT116 Cells; D019073:HT29 Cells; D006801:Humans; D051379:Mice; D008819:Mice, Nude; D008928:Mitochondria / Q000187:drug effects / Q000378:metabolism; D010084:Oxidation-Reduction / Q000187:drug effects; D018384:Oxidative Stress / Q000187:drug effects*; D012402:Rotenone / Q000008:administration & dosage / Q000494:pharmacology*; D047368:Tumor Burden / Q000187:drug effects; D014475:Uncoupling Agents / Q000008:administration & dosage / Q000494:pharmacology; D023041:Xenograft Model Antitumor Assays
D014475:Uncoupling Agents; D012402:Rotenone; D000968:Antimycin A; D003847:Deoxyglucose; D005978:Glutathione; D019803:Glutathione Disulfide